Japan Coronary Stents Market Size Likely to Grow at a CAGR of 4.2% By 2035

Japan market size of coronary stents is estimated to be USD 1.68 billion in 2026 and it is expected to rise to about USD 2.40 billion in 2035 with the CAGR expected to 4.2% during the period 2026-2035.

Japan Coronary Stents Market Revenue and Trends

The coronary stent market in Japan is offering the latest innovative implantable coronary stents such as drug-eluting stent (DES), bioresorbable vascular stents (BVS), bare-metal stent (BMS) and the next gen polymer-free or biodegradable polymer stents designed to be applied in percutaneous coronary intervention (PCI) as the treatment of coronary artery disease, to restore blood flow and prevent restenosis in patients with stable angina, acute coronary syndromes and complex lesions. Japan coronary stents market is expanding at a high rate, owing to the high rate of cardiovascular disease, ageing population, rising volumes of PCI procedure, robust adoption of high end DES technologies and emerging trends of thinner-strut, biodegradable-polymer and completely bioresorbable in interventional cardiology ecosystems.

What are the Factors That Have a Significant Contribution to the Growth of the Japan coronary stents market?

Japan is rapidly aging, high levels of hypertension, diabetes, and atherosclerosis due to smoking increased the need to restore the coronary stent product. With the persistent increase in the population above 65 years and the increase in the use of guideline-based PCI in urban and regional hospitals, there will be an increasing number of patients in need of an effective revascularization solution to enhance their survival and quality of life.

The innovations in technology, such as the introduction of ultra-thin strut DES with biodegradable polymers, stent free of polymer drug-eluting stents, next-generation bioresorbable scaffolds with better radial strength and resorption profiles, and intravascular imaging-guided optimization, have been introduced to improve the long-term patency, reduce stent thrombosis, and support complex PCI. There are other factors that can be considered as strong reimbursement in the national health insurance system, extensive application of optical coherence tomography (OCT), intravascular ultrasound (IVUS), greater emphasis on complex lesion treatment (left main, bifurcations, chronic total occlusions), and government-sponsored cardiovascular prevention programs and quality interventional training.

Segment Insight

By Product Type

Drug-eluting stents (DES) byproducts had as of 2025 far dominated the Japan coronary stents market, largely because Japanese interventional cardiologists have strongly preferred them due to their superior restenosis prevention, long-term safety and performance in challenging anatomies, with further innovation in biodegradable-polymer and polymer-free DES being mentioned by many operators as an even better tool to reducing target lesion failure and promoting the best of PCI outcomes.

By Distribution Channel

The biggest market share is among hospitals and cardiovascular centers that are the main centers of acquisition of the high-end coronary stents, their integration with the sophisticated imaging systems, and high-volume PCI procedures. These channels have since become the preferred channels of distributing coronary stents given the fact that they offer professional expertise in the selection of devices, designing procedure, and follow up after implant and also adherence to Japanese regulatory and reimbursement standards.

Report Scope

Recent Developments

• In October 2025: Abbott Japan was granted extended reimbursement approval, introduced the next-generation XIENCE Skypoint ™ drug-eluting stent with ultrathin struts and enhanced deliverability, and consolidated its leadership in complex PCI operations in leading Japanese cardiac centers.

List of the prominent players in the Japan Coronary Stents Market:

• Terumo Corporation

• Abbott Laboratories

• Medtronic plc

• Boston Scientific Corporation

• B. Braun Melsungen AG

• Biotronik SE & Co. KG

• MicroPort Scientific Corporation

• Cordis Corporation

• Cook Medical LLC

• Japan Medical Device Technology Co. Ltd.

• Others

The Japan Coronary Stents Market is segmented as follows:

By Product Type

• Bare Metal Stents

• Drug-Eluting Stents

o   Polymer-Based DES

o   Polymer-Free DES

• Bioresorbable Vascular Scaffolds

By Biomaterial

• Cobalt-Chromium

• Stainless Steel

• Platinum-Chromium

• Nickel-Titanium Alloy (Nitinol)

By Mode of Delivery

• Balloon-Expandable Stents

• Self-Expanding Stents

By Application

• Acute Myocardial Infarction

• Chronic Total Occlusion

• Stable Angina

• Unstable Angina

By End User

• Hospitals

• Cardiac Catheterization Laboratories

• Ambulatory Surgical Centers